

## Press Release

# **Daiichi Sankyo Announces Termination of Vaccine Business Alliance with Sanofi in Japan**

**Tokyo, Japan (March 31, 2021)** – Daiichi Sankyo Company, Ltd. (hereafter, Daiichi Sankyo) announced today that it will terminate its marketing alliance agreement for the Squarekids® subcutaneous injection syringe (hereafter, Squarekids), a tetravalent combination vaccine<sup>1</sup> and its joint development agreement on pentavalent combination vaccine<sup>2</sup> (hereafter, VN-0105) with Sanofi K.K. (hereafter, Sanofi) effective March 31, 2021.

Daiichi Sankyo decided to suspend the production of Squarekids and its supply to the market due to a problem in the manufacture of pertussis vaccines. Although the company has looked into ways to address the problem with a view to resuming the manufacture and supply of the product, it has recently decided to discontinue production by terminating its agreement with Sanofi, and to discontinue distribution effective March 31, 2021. In addition, Daiichi Sankyo will also end joint development efforts for VN-0105.

Daiichi Sankyo will incur a 15 billion yen loss as it compensates Sanofi for the loss sustained from the termination of the two agreements. The cost will be recorded in the fourth quarter of fiscal year 2020, and the impact of this decision will appear in the company's consolidated financial results for this fiscal year at a later date.

Daiichi Sankyo will continue working with Sanofi to enhance public health and prevent and treat diseases through the manufacture and supply of pharmaceutical products, including vaccines, thereby contributing to promoting people's health.

### **About Daiichi Sankyo**

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio

of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders. For more information, please visit: [www.daiichisankyo.com/](http://www.daiichisankyo.com/).

**Media Contacts:**

**Japan:**

Masashi Kawase

Daiichi Sankyo Co., Ltd.

[kawase.masashi.a2@daiichisankyo.co.jp](mailto:kawase.masashi.a2@daiichisankyo.co.jp)

+81 3 6225 1126 (office)

**Investor Relations Contact:**

[DaiichiSankyoIR@daiichisankyo.co.jp](mailto:DaiichiSankyoIR@daiichisankyo.co.jp)

---

References

<sup>1</sup> Tetravalent combination vaccine is Daiichi Sankyo’s DPT (diphtheria, pertussis, and tetanus) vaccine combined with Sanofi's inactivated polio vaccine.

<sup>2</sup> Pentavalent combination vaccine is the above tetravalent vaccine combined with Sanofi's Hib vaccine.